{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T02:18:05Z","timestamp":1770776285973,"version":"3.50.0"},"reference-count":13,"publisher":"SLACK, Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Objective:<\/jats:title>\n                    <jats:p>This study aimed to describe the treatment burden and long-term visual outcomes in patients with pseudoxanthoma elasticum (PXE), a systemic disease involving calcification fragmentation of elastic fibers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This was a retrospective, cross-sectional analysis of patients diagnosed with PXE between January 2015 and August 2024 in the Vestrum Health treatment and outcomes database. Patients with PXE were identified using ICD-9 and ICD-10 codes and natural language processing. Data were collected on patient demographics, type and number of treatments received, duration of follow-up, and visual acuity at presentation and follow-up visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 248 eyes of 171 patients with PXE were included in the final analysis. The mean (\u00b1 standard deviation [SD]) patient age was 68 (\u00b118) years and 64% were female. The average follow-up duration was 3 years. A total of 197\/248 eyes (79%) developed choroidal neovascularization (CNV). Of these, 70% (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 138\/197) received treatment with an anti-vascular endothelial growth factor (anti-VEGF) injection during the study period. Photodynamic therapy was performed in fewer than five patients. Bevacizumab (61%,\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 84\/138) was the most common anti-VEGF received, followed by aflibercept (43%,\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 59\/138) and ranibizumab (27%,\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 37\/138). The mean (\u00b1 SD) number of injections received in years 1, 3, and 5 were 5.9 (3.0), 5.2 (3.0), and 6.3 (2.9), respectively. For eyes receiving at least one treatment during the study period, the mean presenting visual acuity for those with sufficient follow-up (years 1, 3, and 5) was 59 (Snellen equivalent 20\/66), 60 (Snellen equivalent 20\/63), and 62 (Snellen equivalent 20\/58) letters, respectively. On average, these eyes lost one (58 letters, Snellen equivalent 20\/70), four (56 letters, Snellen equivalent 20\/76), and seven (55 letters, Snellen equivalent 20\/80) letters by years 1, 3, and 5, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>CNV complicates the clinical course of most patients with PXE, necessitating treatment with anti-VEGF injections. This study highlights the refractory nature of PXE-related CNV, with the mean number of injections performed in years 1, 3 and 5 staying relatively constant. On average, eyes lost a moderate degree of vision during the study period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3928\/23258160-20251022-01","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T20:08:46Z","timestamp":1765915726000},"page":"112-116","source":"Crossref","is-referenced-by-count":0,"title":["Long-term Visual Outcomes in Pseudoxanthoma Elasticum-associated Choroidal Neovascularization: A National Database Study"],"prefix":"10.3928","volume":"57","author":[{"given":"Sidra","family":"Zafar","sequence":"first","affiliation":[{"name":"Retina Service, Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitika","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Vestrum Health, Naperville, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josee","family":"Winsor","sequence":"additional","affiliation":[{"name":"Vestrum Health, Naperville, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliott","family":"Sina","sequence":"additional","affiliation":[{"name":"Retina Service, Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudheshna","family":"Vemula","sequence":"additional","affiliation":[{"name":"Retina Service, Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turner D.","family":"Wibbelsman","sequence":"additional","affiliation":[{"name":"Retina Service, Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Boucher","sequence":"additional","affiliation":[{"name":"Vestrum Health, Naperville, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Yonekawa","sequence":"additional","affiliation":[{"name":"Retina Service, Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2012.00289"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0639-8"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(61)90078-x"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31809ff5df"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9121895"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.03.026"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-017-3685-y"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.143461"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.03.022"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.129916"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181d2f11d"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.06.004"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2012.116"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T21:31:11Z","timestamp":1770759071000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20251022-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.3928\/23258160-20251022-01"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20251022-01","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}